Ojamies, P N
Kontro, M
Edgren, H
Ellonen, P
Lagström, S
Almusa, H
Miettinen, T
Eldfors, S http://orcid.org/0000-0001-5056-4750
Tamborero, D
Wennerberg, K
Heckman, C
Porkka, K
Wolf, M
Kallioniemi, O http://orcid.org/0000-0002-3231-0332
Article History
Received: 14 April 2016
Revised: 6 September 2016
Accepted: 12 September 2016
First Online: 31 October 2016
Competing interests
: The authors declare no conflict of interest. The senior authors have received collaborative research grants for other projects as listed. OK has received research funding from Pfizer, Roche and the IMI Predect consortium and is a board member and co-founder of bioinformatics company Medisapiens Ltd, Helsinki, Finland. KP received honoraria and research funding from Bristol-Myers Squibb, Celgene, Novartis and Pfizer. MW received research funding from Pfizer and Bayer Pharma.